SCHEMBL6134367

SCHEMBL6134367

CC(C)n1nc(-c2cnc(N)nc2-c2ccc(Cl)c(Cl)c2)ccc1=O

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ADORA1 P30542 5/20 0.50
DHFR P00374 2/20 0.46
ABL1 P00519 3/20 0.45
SRC P12931 3/20 0.45
ADORA2A P29274 5/20 0.40
KMO O15229 1/20 0.39
PIK3CA P42336 3/20 0.37
MTOR P42345 3/20 0.37
RICTOR Q6R327 1/20 0.37
RPTOR Q8N122 1/20 0.37
MAPKAP1 Q9BPZ7 1/20 0.37
MLST8 Q9BVC4 1/20 0.37
PIK3CD O00329 2/20 0.36
EGFR P00533 2/20 0.36
HCK P08631 2/20 0.36
KDR P35968 2/20 0.36
PIK3CB P42338 2/20 0.36
EPHB4 P54760 2/20 0.36
PRKDC P78527 2/20 0.36
PI4KB Q9UBF8 2/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6134188 0.88 LMNA (0.45) ADORA1ADORA2AADORA2BBMPR1BBMPR1A
SCHEMBL6134599 0.86 ADORA1 (0.53) ADORA1DHFRSRCADORA2AADORA2B
SCHEMBL6134043 0.86 ADORA1 (0.53) ADORA1DHFRSRCADORA2AKMO
SCHEMBL6134359 0.85 RPS6KA3 (0.42) ADORA1ABL1SRCADORA2APIK3CA
SCHEMBL6134159 0.84 RPS6KA3 (0.46) ADORA1ADORA2APIK3CAMTORRICTOR
SCHEMBL6133581 0.84 ADORA1 (0.49) ADORA1ABL1SRCADORA2APIK3CA
SCHEMBL6133386 0.84 KMT2A (0.40) ADORA1ADORA2APIK3CAMTORRICTOR
SCHEMBL6133788 0.84 ADORA1 (0.39) ADORA1ABL1SRCADORA2APIK3CA
SCHEMBL6134450 0.84 ADORA1 (0.50) ADORA1ADORA2AADORA2BBMPR1BBMPR1A
SCHEMBL6133497 0.83 ADORA1 (0.54) ADORA1DHFRABL1SRCADORA2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20050043315-A1 Aminopyrimidine compounds, processes for their preparation and pharmaceutical compositions containing them ASTELLAS PHARMA INC. (JP) 2005-02-24 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050043315-A1 Aminopyrimidine compounds, processes for their preparation and pharmaceutical compositions containing them ADORA2B, ADORA2A, ADORA1 ADORA1 3/4885DHFR 146/4885ABL1 1509/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.